2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses

Background

Nurses provide information and care on cancer treatment side effects prevention and management. Skin toxicities are common side effects and can be associated with treatment dose reduction or discontinuation. Minimizing skin side effects and using photoprotection improve patient outcomes and quality of life.

Methods

The Association Francophone des Soins Oncologiques de Support (AFSOS) and Multinational Association of Supportive Care in Cancer (MASCC) teamed to create consensus recommendations about using dermocosmetics in cancer patients. They assembled a group of international experts from nursing and other disciplines who manage cancer patients. After literature review, the group held a consensus meeting to give guidance on the use of dermocosmetics with oncology treatments.

Results

Dermocosmetics (or cosmeceuticals) are products with therapeutic value in addition to cosmetic. They contain ingredients that can help repair and support the skin barrier by hydrating the skin, maintaining a healthy microbiome. For general recommendations the group agreed: * Start skin care at the same time as cancer interventions known to be associated with skin toxicities, with a goal of preventing and minimizing problems. * Hydration of the skin relieves symptoms and reduces exacerbations of xerosis. * Use cleansers with pH close to 5 and avoid basic or neutral pH cleansers. * Photoprotection should be part of initial recommendations for all Consensus recommendations for the use of dermocosmetics in specific skin toxicities management were also made.

Conclusions

Nurses have an essential role in educating patients about skin care as part of their holistic approach to patient care. This new consensus focuses on the practical and beneficial impact of dermocosmetics to avoid and manage side effects as well as prevent dryness, irritation, and sensitivity. Patient education can help prevent high-grade toxicities and reduce healthcare costs by allowing patients to have an active role in their treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

La Roche Posay.

Disclosure

P. Dielenseger, M. Lacouture, K. Khosrotehrani, G. De Barros Silva, J. Ryan Wolf, E.O. Atenguena, B. Dreno: Financial Interests, Personal and Institutional, Advisory Role: La Roche Posay. D. Kerob: Financial Interests, Personal, Full or part-time Employment: La Roche Posay. All other authors have declared no conflicts of interest.